SCHEMBL24879684

SCHEMBL24879684

CC(O)CNc1c(N)c(Cl)nc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.40
RAD52 P43351 3/20 0.40
KDM4E B2RXH2 3/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GLA P06280 2/20 0.40
RAB9A P51151 2/20 0.40
MITF O75030 1/20 0.40
LMNA P02545 1/20 0.40
TTR P02766 1/20 0.40
TP53 P04637 1/20 0.39
TLR7 Q9NYK1 2/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.38
SLC2A1 P11166 1/20 0.38
APP P05067 2/20 0.38
CHRM2 P08172 1/20 0.38
ADRA2A P08913 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL843109 0.89 KDM4E (0.49) POLBRAD52KDM4EGAAALDH1A1
SCHEMBL31197385 0.89 KDM4E (0.49) POLBRAD52KDM4EGAAALDH1A1
SCHEMBL6107335 0.87 KDM4E (0.41) POLBRAD52KDM4EGAAALDH1A1
SCHEMBL12744366 0.79 APP (0.55) POLBRAD52KDM4EGAAALDH1A1
SCHEMBL28560298 0.79 ALDH1A1 (0.45) POLBKDM4EGAAALDH1A1GLA
SCHEMBL842305 0.78 ATM (0.42) POLBRAD52KDM4EGAAALDH1A1
SCHEMBL1456601 0.78 ACHE (0.53) POLBRAD52KDM4EGAAALDH1A1
SCHEMBL13968056 0.77 KMT2A (0.66) POLBRAD52KDM4EGAAALDH1A1
SCHEMBL6719555 0.77 KDM4E (0.57) POLBRAD52KDM4EGAAALDH1A1
SCHEMBL202694 0.77 POLB (0.68) POLBRAD52KDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230008368-A1 IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008368-A1 IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF TLR4, TLR7, TLR1 POLB 3825/4885RAD52 4253/4885KDM4E 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.